<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://www.psiram.com/en/index.php?action=history&amp;feed=atom&amp;title=Antineoplaston</id>
	<title>Antineoplaston - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://www.psiram.com/en/index.php?action=history&amp;feed=atom&amp;title=Antineoplaston"/>
	<link rel="alternate" type="text/html" href="https://www.psiram.com/en/index.php?title=Antineoplaston&amp;action=history"/>
	<updated>2026-04-10T07:48:49Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.35.7</generator>
	<entry>
		<id>https://www.psiram.com/en/index.php?title=Antineoplaston&amp;diff=2738&amp;oldid=prev</id>
		<title>WikiSysop at 19:17, 4 November 2015</title>
		<link rel="alternate" type="text/html" href="https://www.psiram.com/en/index.php?title=Antineoplaston&amp;diff=2738&amp;oldid=prev"/>
		<updated>2015-11-04T19:17:07Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left diff-editfont-monospace&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 19:17, 4 November 2015&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l67&quot; &gt;Line 67:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 67:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==References==&lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==References==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;references/&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;references/&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt;−&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;[[category:Miracle Therapy]]&lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt;+&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;[[category:Miracle Therapy &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;Cancer&lt;/ins&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>WikiSysop</name></author>
	</entry>
	<entry>
		<id>https://www.psiram.com/en/index.php?title=Antineoplaston&amp;diff=2637&amp;oldid=prev</id>
		<title>Halbmond: /* Legal Issues */</title>
		<link rel="alternate" type="text/html" href="https://www.psiram.com/en/index.php?title=Antineoplaston&amp;diff=2637&amp;oldid=prev"/>
		<updated>2014-12-17T10:48:20Z</updated>

		<summary type="html">&lt;p&gt;&lt;span dir=&quot;auto&quot;&gt;&lt;span class=&quot;autocomment&quot;&gt;Legal Issues&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left diff-editfont-monospace&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 10:48, 17 December 2014&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l38&quot; &gt;Line 38:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 38:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*providing medically unnecessary services to a patient or submitting a billing statement to a patient or a third party payer that the licensee knew or should have known was improper. “Improper” means the billing statement is false, fraudulent, misrepresents services provided, or otherwise does not meet professional standards.&lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*providing medically unnecessary services to a patient or submitting a billing statement to a patient or a third party payer that the licensee knew or should have known was improper. “Improper” means the billing statement is false, fraudulent, misrepresents services provided, or otherwise does not meet professional standards.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt;−&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;The Texas Medical board summoned Burzyński for a hearing to be held on April, 11 2012 which will debate the revocation of his medical licence.&amp;lt;ref&amp;gt;http://www.burzynskimovie.com/index.php?option=com_content&amp;amp;view=article&amp;amp;id=126 Burzyński moviesite, accessed November 26, 2011&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt;+&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;The Texas Medical board summoned Burzyński for a hearing to be held on April, 11 2012 which will debate the revocation of his medical licence.&amp;lt;ref&amp;gt;http://www.burzynskimovie.com/index.php?option=com_content&amp;amp;view=article&amp;amp;id=126 Burzyński moviesite, accessed November 26, 2011&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;&amp;lt;/ref&amp;gt; FDA had put a partial clinical hold on his clinical trials for pediatric patients which even was extended to all clinical trials six months later. FDA inspections of both Burzynski Clinic and Burzynski Research Institute followed in early 2013. However, FDA lifted these bans again in June 2013, despite damning inspection results establishing a rather sweeping non-compliance with FDA constraints by Burzynski. Meanwhile, the Texas Medical Board is again taking action against Burzynski. One of the latest additions to the list of trangressions, the TMB added the use of health care providers with little or no education or skill and representing them to patients as being doctors.&amp;lt;ref&amp;gt;http://www.sciencebasedmedicine.org/the-texas-medical-board-vs-stanislaw-burzynski-2014-edition/ &lt;/ins&gt;&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Clinical Trials==&lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Clinical Trials==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Halbmond</name></author>
	</entry>
	<entry>
		<id>https://www.psiram.com/en/index.php?title=Antineoplaston&amp;diff=2630&amp;oldid=prev</id>
		<title>Halbmond at 09:41, 17 December 2014</title>
		<link rel="alternate" type="text/html" href="https://www.psiram.com/en/index.php?title=Antineoplaston&amp;diff=2630&amp;oldid=prev"/>
		<updated>2014-12-17T09:41:42Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;a href=&quot;https://www.psiram.com/en/index.php?title=Antineoplaston&amp;amp;diff=2630&amp;amp;oldid=2020&quot;&gt;Show changes&lt;/a&gt;</summary>
		<author><name>Halbmond</name></author>
	</entry>
	<entry>
		<id>https://www.psiram.com/en/index.php?title=Antineoplaston&amp;diff=2020&amp;oldid=prev</id>
		<title>Heimdall at 21:34, 30 November 2011</title>
		<link rel="alternate" type="text/html" href="https://www.psiram.com/en/index.php?title=Antineoplaston&amp;diff=2020&amp;oldid=prev"/>
		<updated>2011-11-30T21:34:19Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left diff-editfont-monospace&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 21:34, 30 November 2011&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l44&quot; &gt;Line 44:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 44:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;In December 2007, FDA granted [https://en.wikipedia.org/wiki/Orphan_drug orphan drug] status to Burzyński&amp;#039;s concoctions for the treatment of gliomas, a group of brain tumors hard to treat.&amp;lt;ref name=&amp;quot;HoustonPress&amp;quot;&amp;gt;http://www.houstonpress.com/2009-01-01/news/cancer-doctor-stanislaw-burzynski-sees-himself-as-a-crusading-researcher-not-a-quack/&amp;lt;/ref&amp;gt;  &lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;In December 2007, FDA granted [https://en.wikipedia.org/wiki/Orphan_drug orphan drug] status to Burzyński&amp;#039;s concoctions for the treatment of gliomas, a group of brain tumors hard to treat.&amp;lt;ref name=&amp;quot;HoustonPress&amp;quot;&amp;gt;http://www.houstonpress.com/2009-01-01/news/cancer-doctor-stanislaw-burzynski-sees-himself-as-a-crusading-researcher-not-a-quack/&amp;lt;/ref&amp;gt;  &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt;−&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;An independent review by American Cancer Society also arrived at negative results and recommended  patients not to spend money on antineoplaston treatments since there is no evidence of positive effects in treatment of cancer. A 2004 medical review described this treatment as a &amp;quot;disproven therapy&amp;quot;.&amp;lt;ref name=&amp;quot;acs&amp;quot;&amp;gt;[http://caonline.amcancersoc.org/cgi/reprint/33/1/57.pdf Antineoplastons] - American Cancer Society on Antineoplastons &amp;#039;&amp;#039;CA Cancer J Clin&amp;#039;&amp;#039; 1983;33;57-59, DOI: 10.3322/canjclin.33.1.57&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;[www.cancer.gov/cancertopics/pdq/cam/antineoplastons/healthprofessional/page5 Antineoplastons - Human/Clinical Studies], National Cancer Institute, August 24, 2011&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt;+&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;An independent review by American Cancer Society also arrived at negative results and recommended  patients not to spend money on antineoplaston treatments since there is no evidence of positive effects in treatment of cancer. A 2004 medical review described this treatment as a &amp;quot;disproven therapy&amp;quot;.&amp;lt;ref name=&amp;quot;acs&amp;quot;&amp;gt;[http://caonline.amcancersoc.org/cgi/reprint/33/1/57.pdf Antineoplastons] - American Cancer Society on Antineoplastons &amp;#039;&amp;#039;CA Cancer J Clin&amp;#039;&amp;#039; 1983;33;57-59, DOI: 10.3322/canjclin.33.1.57&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;[&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;http://&lt;/ins&gt;www.cancer.gov/cancertopics/pdq/cam/antineoplastons/healthprofessional/page5 Antineoplastons - Human/Clinical Studies], National Cancer Institute, August 24, 2011&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;In a November 2011 press release Bursynski Clinic listed a &amp;quot;number of studies since 2006&amp;quot; claiming to prove efficacy of the treatment.&amp;lt;ref name=&amp;quot;press_release&amp;quot; /&amp;gt; None of the studies was published in a paper with a high [http://en.wikipedia.org/wiki/Impact_factor impact factor] and most have not been peer reviewed at all. 9 studies are claimed to have been printed by the Journal of Neuro-Oncology which has a good impact factor but in truth were just presented as preliminary results at conferences that were covered by the journal. Contrary to the claim in the press release, there aren’t any scientific studies supporting antineoplason treatment since 2006.&amp;lt;ref&amp;gt;[http://freethoughtblogs.com/blaghag/2011/11/a-look-at-the-burzynski-clinics-publications/ A look at the Burzynski clinic’s publications], Jen McCreight, freethoughtblogs, November 29, 2011&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;[http://freethoughtblogs.com/blaghag/2011/11/more-damning-revelations-about-burzynskis-research/ More damning revelations about Burzynski’s “research”], Jen McCreight, freethoughtblogs, November 30, 2011&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;[http://www.ministryoftruth.me.uk/2011/11/30/burzynski-the-press-release/ Burzynski – The Press Release], Blog: Ministry of Truth, November 30. 2011&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;In a November 2011 press release Bursynski Clinic listed a &amp;quot;number of studies since 2006&amp;quot; claiming to prove efficacy of the treatment.&amp;lt;ref name=&amp;quot;press_release&amp;quot; /&amp;gt; None of the studies was published in a paper with a high [http://en.wikipedia.org/wiki/Impact_factor impact factor] and most have not been peer reviewed at all. 9 studies are claimed to have been printed by the Journal of Neuro-Oncology which has a good impact factor but in truth were just presented as preliminary results at conferences that were covered by the journal. Contrary to the claim in the press release, there aren’t any scientific studies supporting antineoplason treatment since 2006.&amp;lt;ref&amp;gt;[http://freethoughtblogs.com/blaghag/2011/11/a-look-at-the-burzynski-clinics-publications/ A look at the Burzynski clinic’s publications], Jen McCreight, freethoughtblogs, November 29, 2011&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;[http://freethoughtblogs.com/blaghag/2011/11/more-damning-revelations-about-burzynskis-research/ More damning revelations about Burzynski’s “research”], Jen McCreight, freethoughtblogs, November 30, 2011&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;[http://www.ministryoftruth.me.uk/2011/11/30/burzynski-the-press-release/ Burzynski – The Press Release], Blog: Ministry of Truth, November 30. 2011&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Heimdall</name></author>
	</entry>
	<entry>
		<id>https://www.psiram.com/en/index.php?title=Antineoplaston&amp;diff=2019&amp;oldid=prev</id>
		<title>Heimdall at 21:33, 30 November 2011</title>
		<link rel="alternate" type="text/html" href="https://www.psiram.com/en/index.php?title=Antineoplaston&amp;diff=2019&amp;oldid=prev"/>
		<updated>2011-11-30T21:33:34Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left diff-editfont-monospace&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 21:33, 30 November 2011&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l44&quot; &gt;Line 44:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 44:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;In December 2007, FDA granted [https://en.wikipedia.org/wiki/Orphan_drug orphan drug] status to Burzyński&amp;#039;s concoctions for the treatment of gliomas, a group of brain tumors hard to treat.&amp;lt;ref name=&amp;quot;HoustonPress&amp;quot;&amp;gt;http://www.houstonpress.com/2009-01-01/news/cancer-doctor-stanislaw-burzynski-sees-himself-as-a-crusading-researcher-not-a-quack/&amp;lt;/ref&amp;gt;  &lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;In December 2007, FDA granted [https://en.wikipedia.org/wiki/Orphan_drug orphan drug] status to Burzyński&amp;#039;s concoctions for the treatment of gliomas, a group of brain tumors hard to treat.&amp;lt;ref name=&amp;quot;HoustonPress&amp;quot;&amp;gt;http://www.houstonpress.com/2009-01-01/news/cancer-doctor-stanislaw-burzynski-sees-himself-as-a-crusading-researcher-not-a-quack/&amp;lt;/ref&amp;gt;  &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt;−&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;An independent review by American Cancer Society also arrived at negative results and recommended  patients not to spend money on antineoplaston treatments since there is no evidence of positive effects in treatment of cancer. A 2004 medical review described this treatment as a &amp;quot;disproven therapy&amp;quot;.&amp;lt;ref name=&amp;quot;acs&amp;quot;&amp;gt;[http://caonline.amcancersoc.org/cgi/reprint/33/1/57.pdf Antineoplastons] - American Cancer Society on Antineoplastons &amp;#039;&amp;#039;CA Cancer J Clin&amp;#039;&amp;#039; 1983;33;57-59, DOI: 10.3322/canjclin.33.1.57&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;[www.cancer.gov/cancertopics/pdq/cam/antineoplastons/healthprofessional/page5&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;&amp;quot;&amp;gt;&lt;/del&gt;Antineoplastons - Human/Clinical Studies], National Cancer Institute, August 24, 2011&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt;+&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;An independent review by American Cancer Society also arrived at negative results and recommended  patients not to spend money on antineoplaston treatments since there is no evidence of positive effects in treatment of cancer. A 2004 medical review described this treatment as a &amp;quot;disproven therapy&amp;quot;.&amp;lt;ref name=&amp;quot;acs&amp;quot;&amp;gt;[http://caonline.amcancersoc.org/cgi/reprint/33/1/57.pdf Antineoplastons] - American Cancer Society on Antineoplastons &amp;#039;&amp;#039;CA Cancer J Clin&amp;#039;&amp;#039; 1983;33;57-59, DOI: 10.3322/canjclin.33.1.57&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;[www.cancer.gov/cancertopics/pdq/cam/antineoplastons/healthprofessional/page5 Antineoplastons - Human/Clinical Studies], National Cancer Institute, August 24, 2011&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;In a November 2011 press release Bursynski Clinic listed a &amp;quot;number of studies since 2006&amp;quot; claiming to prove efficacy of the treatment.&amp;lt;ref name=&amp;quot;press_release&amp;quot; /&amp;gt; None of the studies was published in a paper with a high [http://en.wikipedia.org/wiki/Impact_factor impact factor] and most have not been peer reviewed at all. 9 studies are claimed to have been printed by the Journal of Neuro-Oncology which has a good impact factor but in truth were just presented as preliminary results at conferences that were covered by the journal. Contrary to the claim in the press release, there aren’t any scientific studies supporting antineoplason treatment since 2006.&amp;lt;ref&amp;gt;[http://freethoughtblogs.com/blaghag/2011/11/a-look-at-the-burzynski-clinics-publications/ A look at the Burzynski clinic’s publications], Jen McCreight, freethoughtblogs, November 29, 2011&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;[http://freethoughtblogs.com/blaghag/2011/11/more-damning-revelations-about-burzynskis-research/ More damning revelations about Burzynski’s “research”], Jen McCreight, freethoughtblogs, November 30, 2011&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;[http://www.ministryoftruth.me.uk/2011/11/30/burzynski-the-press-release/ Burzynski – The Press Release], Blog: Ministry of Truth, November 30. 2011&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;In a November 2011 press release Bursynski Clinic listed a &amp;quot;number of studies since 2006&amp;quot; claiming to prove efficacy of the treatment.&amp;lt;ref name=&amp;quot;press_release&amp;quot; /&amp;gt; None of the studies was published in a paper with a high [http://en.wikipedia.org/wiki/Impact_factor impact factor] and most have not been peer reviewed at all. 9 studies are claimed to have been printed by the Journal of Neuro-Oncology which has a good impact factor but in truth were just presented as preliminary results at conferences that were covered by the journal. Contrary to the claim in the press release, there aren’t any scientific studies supporting antineoplason treatment since 2006.&amp;lt;ref&amp;gt;[http://freethoughtblogs.com/blaghag/2011/11/a-look-at-the-burzynski-clinics-publications/ A look at the Burzynski clinic’s publications], Jen McCreight, freethoughtblogs, November 29, 2011&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;[http://freethoughtblogs.com/blaghag/2011/11/more-damning-revelations-about-burzynskis-research/ More damning revelations about Burzynski’s “research”], Jen McCreight, freethoughtblogs, November 30, 2011&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;[http://www.ministryoftruth.me.uk/2011/11/30/burzynski-the-press-release/ Burzynski – The Press Release], Blog: Ministry of Truth, November 30. 2011&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Heimdall</name></author>
	</entry>
	<entry>
		<id>https://www.psiram.com/en/index.php?title=Antineoplaston&amp;diff=2018&amp;oldid=prev</id>
		<title>Heimdall at 21:31, 30 November 2011</title>
		<link rel="alternate" type="text/html" href="https://www.psiram.com/en/index.php?title=Antineoplaston&amp;diff=2018&amp;oldid=prev"/>
		<updated>2011-11-30T21:31:36Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left diff-editfont-monospace&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 21:31, 30 November 2011&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l24&quot; &gt;Line 24:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 24:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;In 1994 Burzyński was convicted for tax insurance fraud.&amp;lt;ref&amp;gt;[ftp://www.ca5.uscourts.gov/pub/93/93-02071.CV0.wpd.pdf United States Court of Appeals, Fifth Circuit summary judgment], July 28, 1994&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;In 1994 Burzyński was convicted for tax insurance fraud.&amp;lt;ref&amp;gt;[ftp://www.ca5.uscourts.gov/pub/93/93-02071.CV0.wpd.pdf United States Court of Appeals, Fifth Circuit summary judgment], July 28, 1994&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;In 2009, FDA issued a caution against the institute due to violations of regulations for the protection of patients.&amp;lt;ref&amp;gt;[http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm192711.htm Warning letter FDA - Burzynski Research Institute / IRB]&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;In 2009, FDA issued a caution against the institute due to violations of regulations for the protection of patients.&amp;lt;ref&amp;gt;[http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm192711.htm Warning letter FDA - Burzynski Research Institute / IRB]&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt;−&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;In 2010 the Texas State Board of Medical Examiners filed a complaint against Burzyński.&amp;lt;ref&amp;gt;[http://www.ministryoftruth.me.uk/wp-content/uploads/2011/11/tmbvsburzynski.pdf&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;, &lt;/del&gt;Complaint by the Texas Medical Board], December 8, 2010&amp;lt;/ref&amp;gt; The complaint contains the following charges:&amp;lt;ref&amp;gt;[http://www.ministryoftruth.me.uk/2011/11/28/texas-medical-board-vs-burzynski/ Texas Medical Board vs Burzynski], Blog: Ministry of Truth, November 28. 2011&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt;+&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;In 2010 the Texas State Board of Medical Examiners filed a complaint against Burzyński.&amp;lt;ref&amp;gt;[http://www.ministryoftruth.me.uk/wp-content/uploads/2011/11/tmbvsburzynski.pdf Complaint by the Texas Medical Board], December 8, 2010&amp;lt;/ref&amp;gt; The complaint contains the following charges:&amp;lt;ref&amp;gt;[http://www.ministryoftruth.me.uk/2011/11/28/texas-medical-board-vs-burzynski/ Texas Medical Board vs Burzynski], Blog: Ministry of Truth, November 28. 2011&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*failure to practice medicine in an acceptable professional manner consistent with public health and welfare;&lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*failure to practice medicine in an acceptable professional manner consistent with public health and welfare;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Heimdall</name></author>
	</entry>
	<entry>
		<id>https://www.psiram.com/en/index.php?title=Antineoplaston&amp;diff=2017&amp;oldid=prev</id>
		<title>Heimdall at 21:21, 30 November 2011</title>
		<link rel="alternate" type="text/html" href="https://www.psiram.com/en/index.php?title=Antineoplaston&amp;diff=2017&amp;oldid=prev"/>
		<updated>2011-11-30T21:21:35Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left diff-editfont-monospace&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 21:21, 30 November 2011&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l1&quot; &gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;The &amp;#039;&amp;#039;&amp;#039;Antineoplaston-Therapy&amp;#039;&amp;#039;&amp;#039; (ANP) according to [[Stanisław Burzyński]] is an [[unconventional cancer treatments|unconventional cancer treatment]] using so-called „antineoplaston remedies“. Burzyński invented the name for a group of peptides. The [[pseudomedicine|pseudomedical]] therapy is known in US since 1977, evidence for efficacy is not available as of yet. Several fatalities are associated with the therapy&amp;lt;ref&amp;gt;http://www.ncahf.org/nl/1998/9-10.html&amp;lt;/ref&amp;gt;; it is regarded as inappropriate for the treatment of cancer.&amp;lt;ref&amp;gt;Goldberg P, The Antineoplaston Anomaly: How a Drug Was Used for Decades in Thousands of Patients, With No Safety, Efficacy Data, The Cancer Letter 1998 vol 24, 36&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;http://www.quackwatch.com/01QuackeryRelatedTopics/Cancer/burzynski2.html&amp;lt;/ref&amp;gt;  &lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;The &amp;#039;&amp;#039;&amp;#039;Antineoplaston-Therapy&amp;#039;&amp;#039;&amp;#039; (ANP) according to [[Stanisław Burzyński]] is an [[unconventional cancer treatments|unconventional cancer treatment]] using so-called „antineoplaston remedies“. Burzyński invented the name for a group of peptides. The [[pseudomedicine|pseudomedical]] therapy is known in US since 1977, evidence for efficacy is not available as of yet. Several fatalities are associated with the therapy&amp;lt;ref&amp;gt;http://www.ncahf.org/nl/1998/9-10.html&amp;lt;/ref&amp;gt;; it is regarded as inappropriate for the treatment of cancer.&amp;lt;ref&amp;gt;Goldberg P, The Antineoplaston Anomaly: How a Drug Was Used for Decades in Thousands of Patients, With No Safety, Efficacy Data, The Cancer Letter 1998 vol 24, 36&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;http://www.quackwatch.com/01QuackeryRelatedTopics/Cancer/burzynski2.html&amp;lt;/ref&amp;gt;  &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt;−&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Critics of the method were threatened by a marketer of the method in 2011.&amp;lt;ref&amp;gt;[http://www.quackometer.net/blog/2011/11/the-burzynski-clinic-threatens-my-family.html The Burzynski Clinic Threatens My Family.], Quackometer, 24. November 2011&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;[http://rhysmorgan.co/2011/11/threats-from-the-burzynski-clinic/ Threats from The Burzynski Clinic], Blog of Rhys Morgan, November 28, 2011&amp;lt;/ref&amp;gt; After a public outrage, Burzynski&amp;#039;s Clinic issued an apology and a statement that the marketer in question was not &amp;quot;in a professional relationship with the Burzynski Clinic&amp;quot; anymore. The press release confirmed the marketer had been contracted to &amp;quot;stop the dissemination of false and misleading information&amp;quot; about the antineoplaston therapy. Bloggers will be contacted by lawyers to remove false or misleading information.&amp;lt;ref name=&amp;quot;press_release&amp;quot;&amp;gt;[https://docs.google.com/viewer?a=v&amp;amp;pid=explorer&amp;amp;chrome=true&amp;amp;srcid=0BzijOpjuex1bMjE4N2JjOGItZGFlOS00NDE0LTk2YzktMThkYjFiOTU2YjNl&amp;amp;hl=en_US&amp;amp;pli=1 Press Release], Burzynski Clinic, November 29, 2011, accessed November 30, 2011&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt;+&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Critics of the method were threatened by a marketer of the method in 2011.&amp;lt;ref&amp;gt;[http://www.quackometer.net/blog/2011/11/the-burzynski-clinic-threatens-my-family.html The Burzynski Clinic Threatens My Family.], Quackometer, 24. November 2011&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;[http://rhysmorgan.co/2011/11/threats-from-the-burzynski-clinic/ Threats from The Burzynski Clinic], Blog of Rhys Morgan, November 28, 2011&amp;lt;/ref&amp;gt; After a public outrage, Burzynski&amp;#039;s Clinic issued an apology and a statement that the marketer in question was not &amp;quot;in a professional relationship with the Burzynski Clinic&amp;quot; anymore. The press release confirmed the marketer had been contracted to &amp;quot;stop the dissemination of false and misleading information&amp;quot; about the antineoplaston therapy. Bloggers will be contacted by lawyers to remove &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;what is claimed to be &lt;/ins&gt;false or misleading information.&amp;lt;ref name=&amp;quot;press_release&amp;quot;&amp;gt;[https://docs.google.com/viewer?a=v&amp;amp;pid=explorer&amp;amp;chrome=true&amp;amp;srcid=0BzijOpjuex1bMjE4N2JjOGItZGFlOS00NDE0LTk2YzktMThkYjFiOTU2YjNl&amp;amp;hl=en_US&amp;amp;pli=1 Press Release], Burzynski Clinic, November 29, 2011, accessed November 30, 2011&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Stanisław Burzyński==&lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Stanisław Burzyński==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Heimdall</name></author>
	</entry>
	<entry>
		<id>https://www.psiram.com/en/index.php?title=Antineoplaston&amp;diff=2016&amp;oldid=prev</id>
		<title>Heimdall: More info</title>
		<link rel="alternate" type="text/html" href="https://www.psiram.com/en/index.php?title=Antineoplaston&amp;diff=2016&amp;oldid=prev"/>
		<updated>2011-11-30T21:14:17Z</updated>

		<summary type="html">&lt;p&gt;More info&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left diff-editfont-monospace&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 21:14, 30 November 2011&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l1&quot; &gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;The &amp;#039;&amp;#039;&amp;#039;Antineoplaston-Therapy&amp;#039;&amp;#039;&amp;#039; (ANP) according to [[Stanisław Burzyński]] is an [[unconventional cancer treatments|unconventional cancer treatment]] using so-called „antineoplaston remedies“. Burzyński invented the name for a group of peptides. The [[pseudomedicine|pseudomedical]] therapy is known in US since 1977, evidence for efficacy is not available as of yet. Several fatalities are associated with the therapy&amp;lt;ref&amp;gt;http://www.ncahf.org/nl/1998/9-10.html&amp;lt;/ref&amp;gt;; it is regarded as inappropriate for the treatment of cancer.&amp;lt;ref&amp;gt;Goldberg P, The Antineoplaston Anomaly: How a Drug Was Used for Decades in Thousands of Patients, With No Safety, Efficacy Data, The Cancer Letter 1998 vol 24, 36&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;http://www.quackwatch.com/01QuackeryRelatedTopics/Cancer/burzynski2.html&amp;lt;/ref&amp;gt;  &lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;The &amp;#039;&amp;#039;&amp;#039;Antineoplaston-Therapy&amp;#039;&amp;#039;&amp;#039; (ANP) according to [[Stanisław Burzyński]] is an [[unconventional cancer treatments|unconventional cancer treatment]] using so-called „antineoplaston remedies“. Burzyński invented the name for a group of peptides. The [[pseudomedicine|pseudomedical]] therapy is known in US since 1977, evidence for efficacy is not available as of yet. Several fatalities are associated with the therapy&amp;lt;ref&amp;gt;http://www.ncahf.org/nl/1998/9-10.html&amp;lt;/ref&amp;gt;; it is regarded as inappropriate for the treatment of cancer.&amp;lt;ref&amp;gt;Goldberg P, The Antineoplaston Anomaly: How a Drug Was Used for Decades in Thousands of Patients, With No Safety, Efficacy Data, The Cancer Letter 1998 vol 24, 36&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;http://www.quackwatch.com/01QuackeryRelatedTopics/Cancer/burzynski2.html&amp;lt;/ref&amp;gt;  &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt;−&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Critics of the method were threatened by a marketer of the method in 2011.&amp;lt;ref&amp;gt;[http://www.quackometer.net/blog/2011/11/the-burzynski-clinic-threatens-my-family.html The Burzynski Clinic Threatens My Family.], Quackometer, 24. November 2011&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;[http://rhysmorgan.co/2011/11/threats-from-the-burzynski-clinic/ Threats from The Burzynski Clinic], Blog of Rhys Morgan, November 28, 2011&amp;lt;/ref&amp;gt; After a public outrage, Burzynski&amp;#039;s Clinic issued an apology and a statement that the marketer in question was not &amp;quot;in a professional relationship with the Burzynski Clinic&amp;quot; anymore. The press release confirmed the marketer had been contracted to &amp;quot;stop the dissemination of false and misleading information&amp;quot; about the antineoplaston therapy. Bloggers will be contacted by lawyers to remove false or misleading information.&amp;lt;ref&amp;gt;[https://docs.google.com/viewer?a=v&amp;amp;pid=explorer&amp;amp;chrome=true&amp;amp;srcid=0BzijOpjuex1bMjE4N2JjOGItZGFlOS00NDE0LTk2YzktMThkYjFiOTU2YjNl&amp;amp;hl=en_US&amp;amp;pli=1 Press Release], Burzynski Clinic, November 29, 2011, accessed November 30, 2011&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt;+&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Critics of the method were threatened by a marketer of the method in 2011.&amp;lt;ref&amp;gt;[http://www.quackometer.net/blog/2011/11/the-burzynski-clinic-threatens-my-family.html The Burzynski Clinic Threatens My Family.], Quackometer, 24. November 2011&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;[http://rhysmorgan.co/2011/11/threats-from-the-burzynski-clinic/ Threats from The Burzynski Clinic], Blog of Rhys Morgan, November 28, 2011&amp;lt;/ref&amp;gt; After a public outrage, Burzynski&amp;#039;s Clinic issued an apology and a statement that the marketer in question was not &amp;quot;in a professional relationship with the Burzynski Clinic&amp;quot; anymore. The press release confirmed the marketer had been contracted to &amp;quot;stop the dissemination of false and misleading information&amp;quot; about the antineoplaston therapy. Bloggers will be contacted by lawyers to remove false or misleading information.&amp;lt;ref &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;name=&amp;quot;press_release&amp;quot;&lt;/ins&gt;&amp;gt;[https://docs.google.com/viewer?a=v&amp;amp;pid=explorer&amp;amp;chrome=true&amp;amp;srcid=0BzijOpjuex1bMjE4N2JjOGItZGFlOS00NDE0LTk2YzktMThkYjFiOTU2YjNl&amp;amp;hl=en_US&amp;amp;pli=1 Press Release], Burzynski Clinic, November 29, 2011, accessed November 30, 2011&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Stanisław Burzyński==&lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Stanisław Burzyński==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l7&quot; &gt;Line 7:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 7:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Burzyński migrated to the United States in 1970 and was employed at Baylor University in Houston, isolating peptides from rat brains for three years. He received a licence to practice medicine in USA in 1973 and was awarded a three-year grant to study the effects of urinary peptides as an assistant professor. When the grant was not renewed, Burzyński founded his own clinic in Houston.&lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Burzyński migrated to the United States in 1970 and was employed at Baylor University in Houston, isolating peptides from rat brains for three years. He received a licence to practice medicine in USA in 1973 and was awarded a three-year grant to study the effects of urinary peptides as an assistant professor. When the grant was not renewed, Burzyński founded his own clinic in Houston.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt;−&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt;−&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;In 1994 Burzyński was convicted for tax insurance fraud.&amp;lt;ref&amp;gt;[ftp://www.ca5.uscourts.gov/pub/93/93-02071.CV0.wpd.pdf United States Court of Appeals, Fifth Circuit summary judgment], July 28, 1994&amp;lt;/ref&amp;gt; The Texas Medical board summoned him for a hearing on April, 11 2012 which will debate the revocation of his medical licence.&amp;lt;ref&amp;gt;http://www.burzynskimovie.com/index.php?option=com_content&amp;amp;view=article&amp;amp;id=126 Burzyński moviesite, accessed November 26, 2011&amp;lt;/ref&amp;gt;&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Composition of Antineoplastons==&lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Composition of Antineoplastons==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l22&quot; &gt;Line 22:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 20:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Costs==&lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Costs==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;An according therapy is estimated at approximately $ 100,000 per year of treatment. Patients have to pay $ 6,000 prior to the start of treatment and instalments of $ 7,500 to $ 9,000 per month. Most insurance companies consider the therapy unproven and do not reimburse costs.&amp;lt;ref&amp;gt;Aetna Clinical Policy Bulletin, [http://aetna.com/cpb/medical/data/200_299/0240.html Antineoplaston Therapy and Sodium Phenylbutyrate]&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;Blue Cross/Blue Shield Medical Policy, [http://empireblue.com/provider/noapplication/f2/s5/t9/pw_ad084920.pdf Antineoplaston Therapy]&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;[http://www.zenosblog.com/2011/11/big-business-in-texas/ Big business in Texas], Zeno&amp;#039;s Blog, November 26, 2011&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;An according therapy is estimated at approximately $ 100,000 per year of treatment. Patients have to pay $ 6,000 prior to the start of treatment and instalments of $ 7,500 to $ 9,000 per month. Most insurance companies consider the therapy unproven and do not reimburse costs.&amp;lt;ref&amp;gt;Aetna Clinical Policy Bulletin, [http://aetna.com/cpb/medical/data/200_299/0240.html Antineoplaston Therapy and Sodium Phenylbutyrate]&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;Blue Cross/Blue Shield Medical Policy, [http://empireblue.com/provider/noapplication/f2/s5/t9/pw_ad084920.pdf Antineoplaston Therapy]&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;[http://www.zenosblog.com/2011/11/big-business-in-texas/ Big business in Texas], Zeno&amp;#039;s Blog, November 26, 2011&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt;+&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt;+&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;==Legal Issues==&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt;+&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;In 1994 Burzyński was convicted for tax insurance fraud.&amp;lt;ref&amp;gt;[ftp://www.ca5.uscourts.gov/pub/93/93-02071.CV0.wpd.pdf United States Court of Appeals, Fifth Circuit summary judgment], July 28, 1994&amp;lt;/ref&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt;+&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;In 2009, FDA issued a caution against the institute due to violations of regulations for the protection of patients.&amp;lt;ref&amp;gt;[http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm192711.htm Warning letter FDA - Burzynski Research Institute / IRB]&amp;lt;/ref&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt;+&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;In 2010 the Texas State Board of Medical Examiners filed a complaint against Burzyński.&amp;lt;ref&amp;gt;[http://www.ministryoftruth.me.uk/wp-content/uploads/2011/11/tmbvsburzynski.pdf, Complaint by the Texas Medical Board], December 8, 2010&amp;lt;/ref&amp;gt; The complaint contains the following charges:&amp;lt;ref&amp;gt;[http://www.ministryoftruth.me.uk/2011/11/28/texas-medical-board-vs-burzynski/ Texas Medical Board vs Burzynski], Blog: Ministry of Truth, November 28. 2011&amp;lt;/ref&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt;+&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt;+&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;*failure to practice medicine in an acceptable professional manner consistent with public health and welfare;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt;+&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;*failure to meet the standard of care;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt;+&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;*negligence in performing medical services;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt;+&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;*failure to use professional diligence;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt;+&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;*failure to safeguard against potential complications;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt;+&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;*failure to disclose reasonably foreseeable side effects of a procedure or treatment;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt;+&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;*failure to disclose reasonable alternative treatments to a proposed procedure or treatment;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt;+&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;*failure to obtain informed consent from the patient or other person authorized by law to consent to treatment on the patient’s behalf before performing tests, treatments, or procedures; and&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt;+&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;*prescription or administration of a drug in a manner that is not in compliance with Chapter 200 of this title (relating to Standards for Physicians Practicing Complementary and Alternative Medicine) or, that is either not approved by the  ood and Drug Administration (FDA) for use in human beings or does not meet the standards for off-label use, unless an exemption has otherwise been obtained from the FDA.&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt;+&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;*unprofessional or dishonorable conduct that is likely to deceive or defraud the public or injure the public;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt;+&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;*providing medically unnecessary services to a patient or submitting a billing statement to a patient or a third party payer that the licensee knew or should have known was improper. “Improper” means the billing statement is false, fraudulent, misrepresents services provided, or otherwise does not meet professional standards.&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt;+&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt;+&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;The Texas Medical board summoned him for a hearing to be held on April, 11 2012 which will debate the revocation of his medical licence.&amp;lt;ref&amp;gt;http://www.burzynskimovie.com/index.php?option=com_content&amp;amp;view=article&amp;amp;id=126 Burzyński moviesite, accessed November 26, 2011&amp;lt;/ref&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Clinical Trials==&lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Clinical Trials==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Burzyński and his assistants tried to prove clinical efficacy of antineoplastons with several clinical studies. The U.S. government register of clinical trials displays 60 entries (as of November 2011) by Burzynski Research Institute.&amp;lt;ref&amp;gt;[http://clinicaltrials.gov/ct2/results?spons=%22Burzynski+Research+Institute%22&amp;amp;spons_ex=Y Overview: clinical surveys of Burzynski Research Institute]&amp;lt;/ref&amp;gt; The studies are criticized by oncologists due to &amp;quot;flawed research methods&amp;quot; and rated &amp;quot;scientific nonsense&amp;quot;.&amp;lt;ref&amp;gt;[http://www.highbeam.com/doc/1P1-19476029.html Oncologists criticize methods of controversial cancer treatment], Terri Langford, Associated Press, Oktober 1, 1998&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;[http://www.ncbi.nlm.nih.gov/pubmed/15061600 Alternative cancer cures: &amp;quot;unproven&amp;quot; or &amp;quot;disproven&amp;quot;?], Vickers A., PubMed&amp;lt;/ref&amp;gt; Randomized, controlled surveys could not replicate the Burzyński&amp;#039;s results. Between 1991 and 1995, more than a million dollars were spent on independent studies at Mayo Clinic and Memorial Sloan Kettering.&amp;lt;ref&amp;gt;[http://ict.sagepub.com/content/3/1/59.abstract Managing Social Conflict in Complementary and Alternative Medicine Research: The Case of Antineoplastons], Mitchell R. Hammer, PhD, Wayne B. Jonas, MD, doi: 10.1177/1534735404263448, Integr. Cancer Therapies March 2004 vol. 3 no. 1 59-65&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;HoustonPress&amp;quot; /&amp;gt; The studies were cancelled prematurely for ethical reasons because of the method&amp;#039;s poor efficacy.&amp;lt;ref&amp;gt;Burzynski SR, Efficacy of antineoplastons A10 and AS2-1, 1999 Mayo Clin. Proc., vol 74 6 Seiten 641-2 PMID 10377942&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;Buckner JC, Malkin MG, Reed E, Cascino TL, Reid JM, Maes MM, Tong WPY, LIM S, Figg WD: Phase II study of Antineoplaston A10 (NSC 648539) and AS 2-1 (NSC 620261) in patients with recurrent glioma. Mayo Clin Proc, 74, 137-145, 1999&amp;lt;/ref&amp;gt;  &lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Burzyński and his assistants tried to prove clinical efficacy of antineoplastons with several clinical studies. The U.S. government register of clinical trials displays 60 entries (as of November 2011) by Burzynski Research Institute.&amp;lt;ref&amp;gt;[http://clinicaltrials.gov/ct2/results?spons=%22Burzynski+Research+Institute%22&amp;amp;spons_ex=Y Overview: clinical surveys of Burzynski Research Institute]&amp;lt;/ref&amp;gt; The studies are criticized by oncologists due to &amp;quot;flawed research methods&amp;quot; and rated &amp;quot;scientific nonsense&amp;quot;.&amp;lt;ref&amp;gt;[http://www.highbeam.com/doc/1P1-19476029.html Oncologists criticize methods of controversial cancer treatment], Terri Langford, Associated Press, Oktober 1, 1998&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;[http://www.ncbi.nlm.nih.gov/pubmed/15061600 Alternative cancer cures: &amp;quot;unproven&amp;quot; or &amp;quot;disproven&amp;quot;?], Vickers A., PubMed&amp;lt;/ref&amp;gt; Randomized, controlled surveys could not replicate the Burzyński&amp;#039;s results. Between 1991 and 1995, more than a million dollars were spent on independent studies at Mayo Clinic and Memorial Sloan Kettering.&amp;lt;ref&amp;gt;[http://ict.sagepub.com/content/3/1/59.abstract Managing Social Conflict in Complementary and Alternative Medicine Research: The Case of Antineoplastons], Mitchell R. Hammer, PhD, Wayne B. Jonas, MD, doi: 10.1177/1534735404263448, Integr. Cancer Therapies March 2004 vol. 3 no. 1 59-65&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;HoustonPress&amp;quot; /&amp;gt; The studies were cancelled prematurely for ethical reasons because of the method&amp;#039;s poor efficacy.&amp;lt;ref&amp;gt;Burzynski SR, Efficacy of antineoplastons A10 and AS2-1, 1999 Mayo Clin. Proc., vol 74 6 Seiten 641-2 PMID 10377942&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;Buckner JC, Malkin MG, Reed E, Cascino TL, Reid JM, Maes MM, Tong WPY, LIM S, Figg WD: Phase II study of Antineoplaston A10 (NSC 648539) and AS 2-1 (NSC 620261) in patients with recurrent glioma. Mayo Clin Proc, 74, 137-145, 1999&amp;lt;/ref&amp;gt;  &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt;−&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;In December 2007, FDA granted [https://en.wikipedia.org/wiki/Orphan_drug orphan drug] status to Burzyński&amp;#039;s concoctions for the treatment of gliomas, a group of brain tumors hard to treat.&amp;lt;ref name=&amp;quot;HoustonPress&amp;quot;&amp;gt;http://www.houstonpress.com/2009-01-01/news/cancer-doctor-stanislaw-burzynski-sees-himself-as-a-crusading-researcher-not-a-quack/&amp;lt;/ref&amp;gt; &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;In 2009, FDA issued a caution against the institute due &lt;/del&gt;to &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;violations &lt;/del&gt;of &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;regulations for the protection &lt;/del&gt;of &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;patients&lt;/del&gt;.&amp;lt;ref&amp;gt;[http://www.&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;fda&lt;/del&gt;.gov/&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;ICECI&lt;/del&gt;/&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;EnforcementActions&lt;/del&gt;/&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;WarningLetters&lt;/del&gt;/&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;ucm192711.htm Warning letter FDA &lt;/del&gt;- &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;Burzynski Research Institute &lt;/del&gt;/ &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;IRB&lt;/del&gt;]&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt;+&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;In December 2007, FDA granted [https://en.wikipedia.org/wiki/Orphan_drug orphan drug] status to Burzyński&amp;#039;s concoctions for the treatment of gliomas, a group of brain tumors hard to treat.&amp;lt;ref name=&amp;quot;HoustonPress&amp;quot;&amp;gt;http://www.houstonpress.com/2009-01-01/news/cancer-doctor-stanislaw-burzynski-sees-himself-as-a-crusading-researcher-not-a-quack/&amp;lt;/ref&amp;gt;  &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt;+&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;An independent review by American Cancer Society also arrived at negative results and recommended  patients not &lt;/ins&gt;to &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;spend money on antineoplaston treatments since there is no evidence &lt;/ins&gt;of &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;positive effects in treatment &lt;/ins&gt;of &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;cancer. A 2004 medical review described this treatment as a &amp;quot;disproven therapy&amp;quot;&lt;/ins&gt;.&amp;lt;ref &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;name=&amp;quot;acs&amp;quot;&lt;/ins&gt;&amp;gt;[http://&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;caonline.amcancersoc.org/cgi/reprint/33/1/57.pdf Antineoplastons] - American Cancer Society on Antineoplastons &amp;#039;&amp;#039;CA Cancer J Clin&amp;#039;&amp;#039; 1983;33;57-59, DOI: 10.3322/canjclin.33.1.57&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;[&lt;/ins&gt;www.&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;cancer&lt;/ins&gt;.gov/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;cancertopics&lt;/ins&gt;/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;pdq&lt;/ins&gt;/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;cam&lt;/ins&gt;/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;antineoplastons/healthprofessional/page5&amp;quot;&amp;gt;Antineoplastons &lt;/ins&gt;- &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;Human&lt;/ins&gt;/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;Clinical Studies&lt;/ins&gt;]&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;, National Cancer Institute, August 24, 2011&lt;/ins&gt;&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt;−&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;An independent review by American Cancer Society also arrived at negative results and recommended  patients not &lt;/del&gt;to &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;spend money on antineoplaston treatments since there is no evidence of positive effects in treatment &lt;/del&gt;of &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;cancer. A 2004 medical review described this &lt;/del&gt;treatment &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;as a &amp;quot;disproven therapy&amp;quot;&lt;/del&gt;.&amp;lt;ref name=&amp;quot;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;acs&lt;/del&gt;&amp;quot;&amp;gt;[http://&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;caonline&lt;/del&gt;.&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;amcancersoc&lt;/del&gt;.org/&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;cgi&lt;/del&gt;/&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;reprint&lt;/del&gt;/&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;33&lt;/del&gt;/&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;1&lt;/del&gt;/&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;57&lt;/del&gt;.&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;pdf Antineoplastons] &lt;/del&gt;- &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;American Cancer Society on Antineoplastons &amp;#039;&amp;#039;CA Cancer J Clin&amp;#039;&amp;#039; 1983;33;57&lt;/del&gt;-&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;59&lt;/del&gt;, &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;DOI&lt;/del&gt;: &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;10&lt;/del&gt;.&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;3322/canjclin&lt;/del&gt;.&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;33&lt;/del&gt;.&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;1&lt;/del&gt;.&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;57&lt;/del&gt;&amp;lt;/ref&amp;gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;.&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt;+&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;In a November 2011 press release Bursynski Clinic listed a &amp;quot;number of studies since 2006&amp;quot; claiming &lt;/ins&gt;to &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;prove efficacy &lt;/ins&gt;of &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;the &lt;/ins&gt;treatment.&amp;lt;ref name=&amp;quot;&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;press_release&lt;/ins&gt;&amp;quot; &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;/&lt;/ins&gt;&amp;gt; &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;None of the studies was published in a paper with a high &lt;/ins&gt;[http://&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;en&lt;/ins&gt;.&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;wikipedia&lt;/ins&gt;.org/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;wiki/Impact_factor impact factor] and most have not been peer reviewed at all. 9 studies are claimed to have been printed by the Journal of Neuro-Oncology which has a good impact factor but in truth were just presented as preliminary results at conferences that were covered by the journal. Contrary to the claim in the press release, there aren’t any scientific studies supporting antineoplason treatment since 2006.&amp;lt;ref&amp;gt;[http://freethoughtblogs.com&lt;/ins&gt;/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;blaghag&lt;/ins&gt;/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;2011&lt;/ins&gt;/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;11&lt;/ins&gt;/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;a-look-at-the-burzynski-clinics-publications/ A look at the Burzynski clinic’s publications], Jen McCreight, freethoughtblogs, November 29, 2011&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;[http://freethoughtblogs&lt;/ins&gt;.&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;com/blaghag/2011/11/more-damning-revelations-about&lt;/ins&gt;-&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;burzynskis&lt;/ins&gt;-&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;research/ More damning revelations about Burzynski’s “research”], Jen McCreight, freethoughtblogs, November 30&lt;/ins&gt;, &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;2011&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;[http&lt;/ins&gt;:&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;//www&lt;/ins&gt;.&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;ministryoftruth&lt;/ins&gt;.&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;me&lt;/ins&gt;.&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;uk/2011/11/30/burzynski-the-press-release/ Burzynski – The Press Release], Blog: Ministry of Truth, November 30&lt;/ins&gt;. &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;2011&lt;/ins&gt;&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt;−&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;The products are not approved by FDA and may only be used as part of clinical &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;studies&lt;/del&gt;.&lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt;+&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;The products are not approved by FDA and may only be used as part of clinical &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;trials&lt;/ins&gt;.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==The movie &amp;quot;Burzynski - Cancer is Serious Business&amp;quot;==&lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==The movie &amp;quot;Burzynski - Cancer is Serious Business&amp;quot;==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Heimdall</name></author>
	</entry>
	<entry>
		<id>https://www.psiram.com/en/index.php?title=Antineoplaston&amp;diff=2015&amp;oldid=prev</id>
		<title>Heimdall at 16:33, 30 November 2011</title>
		<link rel="alternate" type="text/html" href="https://www.psiram.com/en/index.php?title=Antineoplaston&amp;diff=2015&amp;oldid=prev"/>
		<updated>2011-11-30T16:33:32Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left diff-editfont-monospace&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 16:33, 30 November 2011&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l49&quot; &gt;Line 49:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 49:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==References==&lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==References==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;references/&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;references/&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt;−&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;[[category:&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;Wondertherapy for cancer&lt;/del&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt;+&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;[[category:&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;Miracle Therapy&lt;/ins&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Heimdall</name></author>
	</entry>
	<entry>
		<id>https://www.psiram.com/en/index.php?title=Antineoplaston&amp;diff=2013&amp;oldid=prev</id>
		<title>Halbmond at 15:30, 30 November 2011</title>
		<link rel="alternate" type="text/html" href="https://www.psiram.com/en/index.php?title=Antineoplaston&amp;diff=2013&amp;oldid=prev"/>
		<updated>2011-11-30T15:30:08Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left diff-editfont-monospace&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 15:30, 30 November 2011&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l1&quot; &gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt;−&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;The &amp;#039;&amp;#039;&amp;#039;Antineoplaston-Therapy&amp;#039;&amp;#039;&amp;#039; (ANP) according to [[Stanisław Burzyński]] is an [[unconventional cancer treatments|unconventional cancer treatment]] using so-called „antineoplaston remedies“. Burzyński invented the name for a group of peptides. The [[pseudomedicine|pseudomedical]] therapy is known in US since 1977, evidence for efficacy is not available as of yet. Several fatalities are associated with the therapy&amp;lt;ref&amp;gt;http://www.ncahf.org/nl/1998/9-10.html&amp;lt;/ref&amp;gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;, &lt;/del&gt;it is regarded as inappropriate for the treatment of cancer.&amp;lt;ref&amp;gt;Goldberg P, The Antineoplaston Anomaly: How a Drug Was Used for Decades in Thousands of Patients, With No Safety, Efficacy Data, The Cancer Letter 1998 vol 24, 36&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;http://www.quackwatch.com/01QuackeryRelatedTopics/Cancer/burzynski2.html&amp;lt;/ref&amp;gt;  &lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt;+&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;The &amp;#039;&amp;#039;&amp;#039;Antineoplaston-Therapy&amp;#039;&amp;#039;&amp;#039; (ANP) according to [[Stanisław Burzyński]] is an [[unconventional cancer treatments|unconventional cancer treatment]] using so-called „antineoplaston remedies“. Burzyński invented the name for a group of peptides. The [[pseudomedicine|pseudomedical]] therapy is known in US since 1977, evidence for efficacy is not available as of yet. Several fatalities are associated with the therapy&amp;lt;ref&amp;gt;http://www.ncahf.org/nl/1998/9-10.html&amp;lt;/ref&amp;gt;&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;; &lt;/ins&gt;it is regarded as inappropriate for the treatment of cancer.&amp;lt;ref&amp;gt;Goldberg P, The Antineoplaston Anomaly: How a Drug Was Used for Decades in Thousands of Patients, With No Safety, Efficacy Data, The Cancer Letter 1998 vol 24, 36&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;http://www.quackwatch.com/01QuackeryRelatedTopics/Cancer/burzynski2.html&amp;lt;/ref&amp;gt;  &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt;−&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Critics of the method were threatened &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;in 2011 &lt;/del&gt;by a marketer of the method.&amp;lt;ref&amp;gt;[http://www.quackometer.net/blog/2011/11/the-burzynski-clinic-threatens-my-family.html The Burzynski Clinic Threatens My Family.], Quackometer, 24. November 2011&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;[http://rhysmorgan.co/2011/11/threats-from-the-burzynski-clinic/ Threats from The Burzynski Clinic], Blog of Rhys Morgan, November 28, 2011&amp;lt;/ref&amp;gt; After public outrage, Burzynski Clinic issued an apology and a statement that the marketer in question was not &amp;quot;in a professional relationship with the Burzynski Clinic&amp;quot; anymore. The press release confirmed &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;that &lt;/del&gt;the marketer &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;was &lt;/del&gt;contracted to &amp;quot;stop the dissemination of false and misleading information&amp;quot; about the antineoplaston therapy. Bloggers will be contacted by lawyers to remove false or misleading information.&amp;lt;ref&amp;gt;[https://docs.google.com/viewer?a=v&amp;amp;pid=explorer&amp;amp;chrome=true&amp;amp;srcid=0BzijOpjuex1bMjE4N2JjOGItZGFlOS00NDE0LTk2YzktMThkYjFiOTU2YjNl&amp;amp;hl=en_US&amp;amp;pli=1 Press Release], Burzynski Clinic, November 29, 2011, accessed November 30, 2011&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt;+&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Critics of the method were threatened by a marketer of the method &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;in 2011&lt;/ins&gt;.&amp;lt;ref&amp;gt;[http://www.quackometer.net/blog/2011/11/the-burzynski-clinic-threatens-my-family.html The Burzynski Clinic Threatens My Family.], Quackometer, 24. November 2011&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;[http://rhysmorgan.co/2011/11/threats-from-the-burzynski-clinic/ Threats from The Burzynski Clinic], Blog of Rhys Morgan, November 28, 2011&amp;lt;/ref&amp;gt; After &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;a &lt;/ins&gt;public outrage, Burzynski&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;&amp;#039;s &lt;/ins&gt;Clinic issued an apology and a statement that the marketer in question was not &amp;quot;in a professional relationship with the Burzynski Clinic&amp;quot; anymore. The press release confirmed the marketer &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;had been &lt;/ins&gt;contracted to &amp;quot;stop the dissemination of false and misleading information&amp;quot; about the antineoplaston therapy. Bloggers will be contacted by lawyers to remove false or misleading information.&amp;lt;ref&amp;gt;[https://docs.google.com/viewer?a=v&amp;amp;pid=explorer&amp;amp;chrome=true&amp;amp;srcid=0BzijOpjuex1bMjE4N2JjOGItZGFlOS00NDE0LTk2YzktMThkYjFiOTU2YjNl&amp;amp;hl=en_US&amp;amp;pli=1 Press Release], Burzynski Clinic, November 29, 2011, accessed November 30, 2011&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Stanisław Burzyński==&lt;/div&gt;&lt;/td&gt;&lt;td class=&#039;diff-marker&#039;&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Stanisław Burzyński==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Halbmond</name></author>
	</entry>
</feed>